Similar articles

• Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.

  Bullock R, Cameron A. Bullock R, et al. Curr Med Res Opin. 2002;18(5):258-64. doi: 10.1185/030079902125000813. Curr Med Res Opin. 2002. PMID: 12240787
• Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.

  Wesnes K. Wesnes K. Drugs Today (Barc). 2007 Jun;43(6):349-59. doi: 10.1358/dot.2007.43.6.1107987. Drugs Today (Barc). 2007. PMID: 17612707 Review.
• Rivastigmine: in Parkinson's disease dementia.

  Siddiqui MA, Wagstaff AJ. Siddiqui MA, et al. CNS Drugs. 2006;20(9):739-47; discussion 748-50. doi: 10.2165/00023210-200620090-00003. CNS Drugs. 2006. PMID: 16953649 Review.
• Rivastigmine for dementia associated with Parkinson's disease.

  Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R. Emre M, et al. N Engl J Med. 2004 Dec 9;351(24):2509-18. doi: 10.1056/NEJMoa041470. N Engl J Med. 2004. PMID: 15590953 Clinical Trial.
• Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.

  Kandiah N, Pai MC, Senanarong V, Looi I, Ampil E, Park KW, Karanam AK, Christopher S. Kandiah N, et al. Clin Interv Aging. 2017 Apr 18;12:697-707. doi: 10.2147/CIA.S129145. eCollection 2017. Clin Interv Aging. 2017. PMID: 28458525 Free PMC article. Review.